市場調查報告書
商品編碼
1076234

全球移植物抗宿主病 (GvHD) 治療市場:流行病學、管道分析、市場預測(2022-2027 年)

Graft Versus Host Disease (GvHD) Treatment Market Forecast - Epidemiology & Pipeline Analysis 2022-2027

出版日期: | 出版商: Arizton Advisory & Intelligence | 英文 190 Pages | 訂單完成後即時交付

價格
  • 全貌
  • 簡介
  • 目錄
簡介

移植物抗宿主病 (GvHD) 治療的市場規模預計在預計期間以 7.44% 的複合年增長率增長。

皮質類固醇具有超過 28.97% 的巨大市場份額,因為它們被廣泛推薦用於一線。急性 GvHD (aGvHD) 也顯示出 34.73% 的重要份額,因為 30-50% 的造血幹細胞移植患者發展為急性 GvHD。

本報告調查了全球移植物抗宿主病 (GvHD) 治療市場,概述了 GvHD、8 個主要國家的 HSCT 和異基因 HSCT 以及 8 個主要國家的 aGvHD 和異基因 HSCT 的變化和預測。總結了cGvHD病例數的變化和預測、8個主要國家市場GvHD收入的變化和預測、上市藥物和在研藥物分析、臨床試驗趨勢、競爭環境、主要公司概況等。

目錄

第 1 章 GvHD 概述

第 2 章流行病學/GvHD 概述

  • HSCT及類似HSCT在8個主要國家市場的趨勢和預測
  • 8個主要市場的 HSCT 與異基因 HSCT 對比分析
  • 8個主要國家市場中aGvHD和cGvHD病例數量的變化和預測
  • 8個主要國家市場aGvHD和cGvHD發病率對比分析
  • 美國:HSCT 和類似 HSCT 的過渡/預測
  • 美國:HSCT與異基因HSCT的比較分析
  • 美國:aGvHD 和 cGvHD 病例數量的變化和預測
  • 美國:aGvHD 和 cGvHD 發病率的比較分析
  • 中國:HSCT 和類似 HSCT 的轉變/預測
  • 中國:HSCT與異基因HSCT的比較分析
  • 中國:aGvHD 和 cGvHD 病例數的變化和預測
  • 中國:aGvHD 和 cGvHD 發病率的比較分析
  • 德國:HSCT 和類似 HSCT 的過渡/預測
  • 德國:HSCT與異基因HSCT的比較分析
  • 德國:aGvHD 和 cGvHD 病例數量的變化和預測
  • 德國:aGvHD 和 cGvHD 發病率的比較分析
  • 日本:HSCT 和類似 HSCT 的過渡/預測
  • 日本:HSCT與異基因HSCT的比較分析
  • 日本:aGvHD 和 cGvHD 病例數量的變化和預測
  • 日本:aGvHD 和 cGvHD 發病率的比較分析
  • 法國:HSCT 和類似 HSCT 的過渡/預測
  • 法國:HSCT與異基因HSCT的比較分析
  • 法國:aGvHD 和 cGvHD 病例數量的變化和預測
  • 法國:aGvHD 和 cGvHD 發病率的比較分析
  • 義大利:HSCT 和類似 HSCT 的過渡/預測
  • 義大利:HSCT與異基因HSCT的比較分析
  • 義大利:aGvHD 和 cGvHD 病例數量的變化和預測
  • 義大利:aGvHD 和 cGvHD 發病率的比較分析
  • 英國:HSCT 和類似 HSCT 的過渡/預測
  • 英國:HSCT 與異基因 HSCT 的比較分析
  • 英國:aGvHD 和 cGvHD 病例數量的變化和預測
  • 英國:aGvHD 和 cGvHD 發生率的比較分析
  • 西班牙:HSCT 和類似 HSCT 的過渡/預測
  • 西班牙:HSCT與異基因HSCT的比較分析
  • 西班牙:aGvHD 和 cGvHD 病例數量的變化和預測
  • 西班牙:aGvHD 和 cGvHD 發病率的比較分析

第 3 章 GvHD 市場規模/概述

  • 8個主要市場的 GvHD 收入趨勢和預測
  • 8個主要市場的 GvHD 收入趨勢和預測:快照
  • 8個主要國家市場上主要批准和非適應症的 GvHD 藥物
  • 8個主要市場的收入趨勢/預測:按治療類型/性別/藥物類別
  • 美國:GvHD 收入的趨勢和預測
  • 美國:GvHD 收入趨勢/預測:快照
  • 美國:收入趨勢/預測:按治療類型/性別/藥物類別
  • 中國:GvHD 收入的趨勢和預測
  • 中國:GvHD 收入趨勢/預測:快照
  • 中國:收入趨勢/預測:按治療類型/性別/藥物類別
  • 德國:GvHD 收入的趨勢和預測
  • 德國:GvHD 收入趨勢/預測:快照
  • 德國:收入趨勢/預測:治療類型/性別/藥物類別
  • 日本:GvHD 收入的趨勢和預測
  • 日本:GvHD 收入趨勢/預測:快照
  • 日本:收入趨勢/預測:治療類型/性別/藥物類別
  • 法國:GvHD 收入的趨勢和預測
  • 法國:GvHD 收益趨勢/預測:快照
  • 法國:收入趨勢/預測:治療類型/性別/藥物類別
  • 義大利:GvHD 收入的趨勢和預測
  • 義大利:GvHD 收益趨勢/預測:快照
  • 義大利:收入趨勢/預測:治療類型/性別/藥物類別
  • 英國:GvHD 收入的趨勢和預測
  • 英國:GvHD 收入趨勢/預測:快照
  • 英國:收入趨勢/預測:按治療類型/性別/藥物類別
  • 西班牙:GvHD 收入的趨勢和預測
  • 西班牙:GvHD 收入趨勢/預測:快照
  • 西班牙:收入趨勢/預測:按治療類型/性別/藥物類別

第 4 章 GvHD 上市藥物概述

  • GvHD 非處方藥:概述
  • GvHD 非處方藥:總結

第 5 章 GvHD 管線藥物概述

  • GvHD 管線藥物:概述
  • GvHD 管道藥物:快照
  • GvHD 管道藥物概述/快照:按疾病類型
  • GvHD 管道藥物概述/快照:按開發階段
  • GvHD 管道藥物概述 □ 快照:按給藥途徑
  • GvHD 管道藥物概述/快照:按作用機制
  • GvHD 管道藥物概述/快照:按分子類型
  • GvHD 管道藥物概述/快照:按地區

第 6 章 GvHD:臨床試驗概述

  • GvHD 臨床試驗總結:快照
  • GvHD 臨床試驗概述:按招募狀態
  • GvHD 臨床試驗概述:按產品類型
  • GvHD 臨床試驗概述:按給藥途徑
  • GvHD 臨床試驗概述:按分子類型
  • GvHD 臨床試驗概述:按地區劃分

第 7 章 GvHD:市場動態

  • 市場促進因素
  • 市場抑制因素
  • 市場趨勢

第 8 章 GvHD:競爭態勢

  • GvHD 競賽:上市藥物
  • 未滿足的需求/戰略建議
  • 非適應症和晚期藥物的競爭性評估
  • 主要公司簡介
  • GvHD 藥物市場的競爭情景
  • 其他領先的公司簡介
  • 主要公司概覽
  • GvHD 競爭:管道藥物
  • 主要初創企業簡介
  • 主要初創公司概覽
  • 其他領先公司的簡介

第 9 章 GvHD:其他

  • 臨時藥品審批時間表
  • 主要監管名稱
  • 主要裡程碑
  • 合同/協作
  • 暫停/停產產品

第 10 章附錄

目錄
Product Code: Sample_Graft Versus Host Disease (GvHD) Treatment Market Forecast - Epidemiology & Pipeline Analysis 2022-2027_Arizton.pdf

The report considers the present scenario of the graft versus host disease market and its market dynamics for the period 2022-2027. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyses leading companies and several other prominent companies operating in the market.

The graft versus host disease market to grow at a CAGR of 7.44% during 2021-2027.

SEGMENT ANALYSIS

  • Corticosteroids accounted for the significant share of more than 28.97% in the global GvHD treatment market due to its wide recommendation in front line setting.
  • The acute GVHD (aGVHD) accounted for a significant share of 34.73% in the global graft versus host disease (GVHD) treatment market due to 30% to 50% of hematopoietic stem cell transplant recipients develop acute GVHD.
  • Males are accounted for the significant share of 59.64% in the global GvHD treatment market due to rise in number of hematopoietic stem cell transplantations.

Market Segmentation by Drug Class

  • Corticosteroids
  • Kinase Inhibitors
  • Calcineurin Inhibitors
  • TNF-Alpha Inhibitors
  • Other Class of Drugs

Market Segmentation by Treatment Type

  • GVHD Prophylaxis
  • Chronic GVHD
  • Acute GVHD

Market Segmentation by Gender Type

  • Males
  • Females

GEOGRAPHIC ANALYSIS

  • The United States dominated the graft versus host disease (GVHD) treatment market by geography. However, China is expected to grow faster with a high CAGR in the market. The rise in incidence and prevalence of GVHD patients, presence of key players, and rise in access to health care due to well-established healthcare infrastructure and extensive reach of novel therapeutics are largely driving the United States market.

Market Segmentation by Geography

  • North America
    • US
  • Europe
    • France
    • Germany
    • Italy
    • UK
    • Spain
  • APAC
    • China
    • Japan

VENDOR ANALYSIS

  • With more than 134+ molecules in various stages of development, it is expected that new vendors are likely to enter into the market with novel mechanism of action and better safety and efficacy profiles compared to the existing patented commercial drugs for treating GVHD.

Key Players

  • Incyte
  • Pharmacyclics
  • Bristol-Myers Squibb
  • JCR Pharmaceuticals Co., Ltd.
  • Takeda Pharmaceutical Co Ltd (Takeda)
  • MaaT Pharma
  • XeniKos
  • Medac GmbH
  • Mesoblast
  • Kadmon
  • Jazz Pharmaceuticals
  • Gsk
  • Novartis
  • Syndax Pharmaceuticals Inc

Other Prominent Vendors

  • Neovii
  • ElsaLys Biotech
  • Mallinckrodt
  • Regimmune
  • Roche
  • Altrubio
  • CTTQ
  • Equillium
  • Janssen (johnson & johnson)
  • ASC Therapeutics
  • MSD
  • Genentech
  • Sun Pharma
  • Mink Therapeutics
  • Pluristem

The Report Covers The following details:

  • Detailed overview of GVHD, including disease definition, classification, diagnosis, and treatment pattern
  • Overview of the global graft versus host disease treatment market trends in the eight major markets (8MM)
  • Historical, current, and projected patient pool of GVHD in the eight major markets (8MM) for the 2018 - 2027 period
  • Disease, Gender, and Drug Class segmentations of the GVHD in the eight major markets (8MM)
  • Historical, current, and projected market size & forecast of GVHD in eight major markets (8MM) for the 2018 - 2027 period
  • In-depth analysis of the market segments, which includes products, treatment, and competitor analysis
  • Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape
  • Comprehensive data on emerging trends, market drivers, growth opportunities, and restraints
  • Detailed overview of marketed drugs with key coverage of developmental activities, including sponsor name, approved indication, territory, collaborations, licensing, mergers and acquisitions, regulatory designations, and other product-related activities
  • Detailed overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for GVHD across the complete product development cycle, including all clinical and non-clinical stages
  • Detailed overview of clinical trial activities and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and Geography type for GVHD across all clinical stages
  • Coverage of dormant and discontinued pipeline projects along with the reasons across GVHD
  • Coverage of major milestones (product approvals/launches timelines, clinical trial result publications, regulatory designations, licensing & collaborations, research & development progress of pipeline assets) in the GVHD space

TABLE OF CONTENTS

CHAPTER - 1 GVHD OVERVIEW

  • Graft Versus Host Disease - An Overview

CHAPTER - 2 GVHD EPIDEMIOLOGY & OVERVIEW

  • 8MM Historic & Projected Volume of HSCT & Allogeneic - HSCT
  • 8MM Comparative Analysis of HSCT & Allogeneic - HSCT
  • 8MM Historic & Projected Volume of incidence of aGVHD & cGVHD
  • 8MM Comparative Analysis of incidence of aGVHD & cGVHD
  • US Historic & Projected Volume of HSCT & Allogeneic - HSCT
  • US Comparative Analysis of HSCT & Allogeneic - HSCT
  • US Historic & Projected Volume of incidence of aGVHD & cGVHD
  • US Comparative Analysis of incidence of aGVHD & cGVHD
  • China Historic & Projected Volume of HSCT & Allogeneic - HSCT
  • China Comparative Analysis of HSCT & Allogeneic - HSCT
  • China Historic & Projected Volume of incidence of aGVHD & cGVHD
  • China Comparative Analysis of incidence of aGVHD & cGVHD
  • Germany Historic & Projected Volume of HSCT & Allogeneic - HSCT
  • Germany Comparative Analysis of HSCT & Allogeneic - HSCT
  • Germany Historic & Projected Volume of incidence of aGVHD & cGVHD
  • Germany Comparative Analysis of incidence of aGVHD & cGVHD
  • Japan Historic & Projected Volume of HSCT & Allogeneic - HSCT
  • Japan Comparative Analysis of HSCT & Allogeneic - HSCT
  • Japan Historic & Projected Volume of incidence of aGVHD & cGVHD
  • Japan Comparative Analysis of incidence of aGVHD & cGVHD
  • France Historic & Projected Volume of HSCT & Allogeneic - HSCT
  • France Comparative Analysis of HSCT & Allogeneic - HSCT
  • France Historic & Projected Volume of incidence of aGVHD & cGVHD
  • France Comparative Analysis of incidence of aGVHD & cGVHD
  • Italy Historic & Projected Volume of HSCT & Allogeneic - HSCT
  • Italy Comparative Analysis of HSCT & Allogeneic - HSCT
  • Italy Historic & Projected Volume of incidence of aGVHD & cGVHD
  • Italy Comparative Analysis of incidence of aGVHD & cGVHD
  • UK Historic & Projected Volume of HSCT & Allogeneic - HSCT
  • UK Comparative Analysis of HSCT & Allogeneic - HSCT
  • UK Historic & Projected Volume of incidence of aGVHD & cGVHD
  • UK Comparative Analysis of incidence of aGVHD & cGVHD
  • Spain Historic & Projected Volume of HSCT & Allogeneic - HSCT
  • Spain Comparative Analysis of HSCT & Allogeneic - HSCT
  • Spain Historic & Projected Volume of incidence of aGVHD & cGVHD
  • Spain Comparative Analysis of incidence of aGVHD & cGVHD

CHAPTER - 3 GVHD MARKET SIZE & OVERVIEW

  • 8MM Historic & Projected Revenue of GVHD
  • 8MM Historic & Projected Revenue of GVHD Snapshot
  • 8MM Major Approved & Off-label Drugs in GVHD
  • 8MM Historic & Projected Revenue Segmentation by Treatment type, Gender type & Drug Class
  • US Historic & Projected Revenue of GVHD
  • US Historic & Projected Revenue of GVHD Snapshot
  • US Historic & Projected Revenue Segmentation by Treatment type, Gender type & Drug Class
  • China Historic & Projected Revenue of GVHD
  • China Historic & Projected Revenue of GVHD Snapshot
  • China Historic & Projected Revenue Segmentation by Treatment type, Gender type & Drug Class
  • Germany Historic & Projected Revenue of GVHD
  • Germany Historic & Projected Revenue of GVHD Snapshot
  • Germany Historic & Projected Revenue Segmentation by Treatment type, Gender type & Drug Class
  • Japan Historic & Projected Revenue of GVHD
  • Japan Historic & Projected Revenue of GVHD Snapshot
  • Japan Historic & Projected Revenue Segmentation by Treatment type, Gender type & Drug Class
  • France Historic & Projected Revenue of GVHD
  • France Historic & Projected Revenue of GVHD Snapshot
  • France Historic & Projected Revenue Segmentation by Treatment type, Gender type & Drug Class
  • Italy Historic & Projected Revenue of GVHD
  • Italy Historic & Projected Revenue of GVHD Snapshot
  • Italy Historic & Projected Revenue Segmentation by Treatment type, Gender type & Drug Class
  • UK Historic & Projected Revenue of GVHD
  • UK Historic & Projected Revenue of GVHD Snapshot
  • UK Historic & Projected Revenue Segmentation by Treatment type, Gender type & Drug Class
  • Spain Historic & Projected Revenue of GVHD
  • Spain Historic & Projected Revenue of GVHD Snapshot
  • Spain Historic & Projected Revenue Segmentation by Treatment type, Gender type & Drug Class

CHAPTER - 4 GVHD MARKETED DRUGS OVERVIEW

  • GVHD Marketed Drugs - An Overview
  • GVHD Marketed Drugs - Summary

CHAPTER - 5 GVHD PIPELINE DRUGS OVERVIEW

  • GVHD Pipeline Drugs - An Overview
  • GVHD Pipeline Drugs - Snapshot
  • GVHD Pipeline Drugs Overview & Snapshot - By Disease type
  • GVHD Pipeline Drugs Overview & Snapshot - By Development Phase
  • GVHD Pipeline Drugs Overview & Snapshot - By Route of Administration
  • GVHD Pipeline Drugs Overview & Snapshot - By Mechanism of Action
  • GVHD Pipeline Drugs Overview & Snapshot - By Molecule type
  • GVHD Pipeline Drugs Overview & Snapshot - By Geography type

CHAPTER - 6 GVHD CLINICAL TRIALS OVERVIEW

  • GVHD Clinical Trials Overview Snapshot
  • GVHD Clinical Trials Overview - By Recruitment Status
  • GVHD Clinical Trials Overview - By Product type
  • GVHD Clinical Trials Overview - By Route of Administration
  • GVHD Clinical Trials Overview - By Molecule type
  • GVHD Clinical Trials Overview - By Geography type

CHAPTER - 7 GVHD MARKET DYNAMICS

  • GVHD Treatment Market Drivers
  • GVHD Treatment Market Constraints
  • GVHD Treatment Market Trends

CHAPTER - 8 GVHD COMPETITIVE LANDSCAPE

  • GVHD Competitive Landscape - Marketed Drugs
  • Unmet Needs & Strategic Recommendations
  • Competitive Assessment of Off-label & Late-stage Drugs
  • Key Company Profiles
  • Competitive Scenario of GVHD Treatment Market
  • Other Prominent Company Profiles
  • Key Company Overviews
  • GVHD Competitive Landscape - Pipeline Drugs
  • Key Emerging Company Profiles
  • Key Emerging Company Overviews
  • Other Prominent Company Profiles

CHAPTER - 9 GVHD MISCELLANEOUS

  • Key Tentative Drug Approvals Timeline
  • Key Regulatory Designations
  • Key Milestones
  • Deals & Collaborations
  • Inactive/Discontinued/Dormant Products

CHAPTER - 10 APPENDIX

  • About Arizton
  • Research Methodology
  • List of Abbreviations

LIST OF EXHIBITS

  • Exhibit 1 HISTORIC & PROJECTED VOLUME OF HSCT IN 8 MAJOR MARKETS
  • Exhibit 2 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN 8 MAJOR MARKETS
  • Exhibit 3 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN 8 MAJOR MARKETS (2018-2020)
  • Exhibit 4 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN 8 MAJOR MARKETS (2021 - 2027)
  • Exhibit 5 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN 8 MAJOR MARKETS

Exhibit 6 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN 8 MAJOR MARKETS

  • Exhibit 7 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN 8 MAJOR MARKETS (2018-2020)
  • Exhibit 8 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN 8 MAJOR MARKETS (2021-2027)
  • Exhibit 9 HISTORIC & PROJECTED VOLUME OF HSCT IN UNITED STATES
  • Exhibit 10 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN UNITED STATES
  • Exhibit 11 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN UNITED STATES (2018-2020)

Exhibit 12 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN UNITED STATES (2021-2027)

  • Exhibit 13 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN UNITED STATES
  • Exhibit 14 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN UNITED STATES
  • Exhibit 15 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN UNITED STATES (2018-2020)
  • Exhibit 16 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN UNITED STATES (2021-2027)
  • Exhibit 17 HISTORIC & PROJECTED VOLUME OF HSCT IN CHINA

Exhibit 18 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN CHINA

  • Exhibit 19 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN CHINA (2018-2020)
  • Exhibit 20 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN CHINA (2021-2027)
  • Exhibit 21 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN CHINA

Exhibit 22 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN CHINA

  • Exhibit 23 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN CHINA (2018-2020)
  • Exhibit 24 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN CHINA (2021-2027)
  • Exhibit 25 HISTORIC & PROJECTED VOLUME OF HSCT IN GERMANY

Exhibit 26 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN GERMANY

  • Exhibit 27 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN GERMANY (2018-2020)
  • Exhibit 28 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN GERMANY (2021-2027)
  • Exhibit 29 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN GERMANY

Exhibit 30 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN GERMANY

  • Exhibit 31 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN GERMANY (2018-2020)
  • Exhibit 32 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN GERMANY (2021-2027)
  • Exhibit 33 HISTORIC & PROJECTED VOLUME OF HSCT IN JAPAN
  • Exhibit 34 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN JAPAN
  • Exhibit 35 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN JAPAN (2018-2020)
  • Exhibit 36 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN JAPAN (2021-2027)
  • Exhibit 37 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN JAPAN

Exhibit 38 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN JAPAN

  • Exhibit 39 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN JAPAN (2018-2020)
  • Exhibit 40 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN JAPAN (2021-2027)
  • Exhibit 41 HISTORIC & PROJECTED VOLUME OF HSCT IN FRANCE
  • Exhibit 42 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN FRANCE
  • Exhibit 43 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN FRANCE (2018-2020)

Exhibit 44 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN FRANCE (2021-2027)

  • Exhibit 45 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN FRANCE

Exhibit 46 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN FRANCE

  • Exhibit 47 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN FRANCE (2018-2020)
  • Exhibit 48 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN FRANCE (2021-2027)
  • Exhibit 49 HISTORIC & PROJECTED VOLUME OF HSCT IN ITALY

Exhibit 50 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN ITALY

  • Exhibit 51 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN ITALY (2018-2020)
  • Exhibit 52 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN ITALY (2021-2027)
  • Exhibit 53 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN ITALY

Exhibit 54 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN ITALY

  • Exhibit 55 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN ITALY (2018-2020)
  • Exhibit 56 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN ITALY (2021-2027)
  • Exhibit 57 HISTORIC & PROJECTED VOLUME OF HSCT IN UNITED KINGDOM

Exhibit 58 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN UNITED KINGDOM

  • Exhibit 59 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN UNITED KINGDOM (2018-2020)
  • Exhibit 60 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN UNITED KINGDOM (2021-2027)
  • Exhibit 61 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN UNITED KINGDOM

Exhibit 62 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN UNITED KINGDOM

  • Exhibit 63 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN UNITED KINGDOM (2018-2020)
  • Exhibit 64 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN UNITED KINGDOM (2021-2027)
  • Exhibit 65 HISTORIC & PROJECTED VOLUME OF HSCT IN SPAIN

Exhibit 66 HISTORIC & PROJECTED VOLUME OF ALLOGENEIC HSCT IN SPAIN

  • Exhibit 67 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN SPAIN (2018-2020)
  • Exhibit 68 COMPARATIVE ANALYSIS OF HSCT & ALLO-HSCT IN SPAIN (2021-2027)
  • Exhibit 69 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ACUTE GVHD IN SPAIN

Exhibit 70 HISTORIC & PROJECTED VOLUME OF INCIDENCE OF CHRONIC GVHD IN SPAIN

  • Exhibit 71 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN SPAIN (2018-2020)
  • Exhibit 72 COMPARATIVE ANALYSIS OF INCIDENCE OF ACUTE & CHRONIC GVHD IN SPAIN (2021-2027)
  • Exhibit 73 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN 8 MAJOR MARKETS
  • Exhibit 74 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN 8 MAJOR MARKETS
  • Exhibit 75 MAJOR APPROVED & OFF-LABEL DRUGS IN GVHD TREATMENT MARKET
  • Exhibit 76 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN 8 MAJOR MARKETS
  • Exhibit 77 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN 8 MAJOR MARKETS
  • Exhibit 78 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN 8 MAJOR MARKETS
  • Exhibit 79 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN UNITED STATES
  • Exhibit 80 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN UNITED STATES
  • Exhibit 81 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN UNITED STATES
  • Exhibit 82 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN UNITED STATES
  • Exhibit 83 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN UNITED STATES
  • Exhibit 84 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN CHINA
  • Exhibit 85 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN CHINA
  • Exhibit 86 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN CHINA
  • Exhibit 87 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN CHINA
  • Exhibit 88 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN CHINA
  • Exhibit 89 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN GERMANY
  • Exhibit 90 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN GERMANY
  • Exhibit 91 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN GERMANY
  • Exhibit 92 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN GERMANY
  • Exhibit 93 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN GERMANY
  • Exhibit 94 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN JAPAN
  • Exhibit 95 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN JAPAN
  • Exhibit 96 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN JAPAN
  • Exhibit 97 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN JAPAN
  • Exhibit 98 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN JAPAN
  • Exhibit 99 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN FRANCE
  • Exhibit 100 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN FRANCE
  • Exhibit 101 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN FRANCE
  • Exhibit 102 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN FRANCE
  • Exhibit 103 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN FRANCE
  • Exhibit 104 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN ITALY
  • Exhibit 105 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN ITALY
  • Exhibit 106 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN ITALY
  • Exhibit 107 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN ITALY
  • Exhibit 108 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN ITALY
  • Exhibit 109 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN UNITED KINGDOM
  • Exhibit 110 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN UNITED KINGDOM
  • Exhibit 111 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN UNITED KINGDOM
  • Exhibit 112 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN UNITED KINGDOM
  • Exhibit 113 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN UNITED KINGDOM
  • Exhibit 114 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET IN SPAIN
  • Exhibit 115 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION IN SPAIN
  • Exhibit 116 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY TREATMENT TYPE IN SPAIN
  • Exhibit 117 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY GENDER IN SPAIN
  • Exhibit 118 HISTORIC & PROJECTED REVENUE OF GVHD TREATMENT MARKET SEGMENTATION BY DRUG CLASS IN SPAIN
  • Exhibit 119 MARKETED DRUGS OVERVIEW IN GVHD TREATMENT MARKET
  • Exhibit 120 GVHD PIPELINE DRUGS OVERVIEW SNAPSHOT
  • Exhibit 121 GVHD PIPELINE DRUGS LANDSCAPE SNAPSHOT
  • Exhibit 122 GVHD PIPELINE DRUGS OVERVIEW BY DISEASE TYPE
  • Exhibit 123 GVHD PIPELINE DRUGS OVERVIEW BY DEVELOPMENT PHASE
  • Exhibit 124 GVHD PIPELINE DRUGS OVERVIEW BY ROUTE OF ADMINISTRATION
  • Exhibit 125 GVHD PIPELINE DRUGS OVERVIEW BY MECHANISM OF ACTION
  • Exhibit 126 GVHD PIPELINE DRUGS OVERVIEW BY MOLECULE TYPE
  • Exhibit 127 GVHD PIPELINE DRUGS OVERVIEW BY GEOGRAPHY TYPE
  • Exhibit 128 KEY TENTATIVE TIMELINE APPROVALS OF PIPELINE DRUHS IN GVHD
  • Exhibit 129 KEY REGULATORY DESIGNATIONS OF PIPELINE DRUGS IN GVHD
  • Exhibit 130 INACTIVE/DISCONTINUED PIPELINE DRUGS IN GVHD
  • Exhibit 131 COMPETITIVE ASSESSMENT OF GVHD PROPHYLAXIS OFF-LABEL & LATE-STAGE PIPELINE DRUGS
  • Exhibit 132 COMPETITIVE ASSESSMENT OF ACUTE GVHD OFF-LABEL & LATE-STAGE PIPELINE DRUGS
  • Exhibit 133 COMPETITIVE ASSESSMENT OF CHRONIC GVHD OFF-LABEL & LATE-STAGE PIPELINE DRUGS
  • Exhibit 134 GVHD CLINICAL TRIALS OVERVIEW SNAPSHOT

LIST OF TABLES

Table 1 KEY MARKET DRIVERS IN GVHD TREATMENT MARKET

Table 2 KEY MARKET CONSTRAINTS IN GVHD TREATMENT MARKET

Table 3 KEY MARKET TRENDS IN GVHD TREATMENT MARKET

Table 4 COMPETITIVE LANDSCAPE OF MARKETED DRUGS IN GVHD TREATMENT MARKET

Table 5 COMPETITIVE SCENARIO OF GVHD TREATMENT MARKET

Table 6 COMPETITIVE LANDSCAPE OF PIPELINE DRUGS IN GVHD TREATMENT MARKET